Who are NOVOCART® 3D plus's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Low-dose PRP, Platelet Rich Plasma (PRP), PCRA (Intermittent injection), Autologous platelets rich plasma, Leukocyte rich platelet rich plasma, 3ml-Rejuvinex.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/novocart-3d-plus.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

NOVOCART® 3D plus — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

NOVOCART® 3D plus (NOVOCART® 3D plus) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Autologous cell therapy. Area: Orthopedics / Regenerative Medicine.

phase 3 Autologous cell therapy Orthopedics / Regenerative Medicine Small molecule Live · refreshed every 30 min

Target snapshot

NOVOCART® 3D plus (NOVOCART® 3D plus) — Tetec AG. NOVOCART® 3D plus is an autologous chondrocyte implant that regenerates cartilage tissue by delivering the patient's own expanded cartilage cells into a defect site.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
NOVOCART® 3D plus TARGET	NOVOCART® 3D plus	Tetec AG	phase 3	Autologous cell therapy
Low-dose PRP	Low-dose PRP	Hospital for Special Surgery, New York	marketed	Autologous cell therapy / Regenerative medicine product
Platelet Rich Plasma (PRP)	Platelet Rich Plasma (PRP)	Aspetar	marketed	Autologous cell therapy / Regenerative medicine
PCRA (Intermittent injection)	PCRA (Intermittent injection)	Örebro University, Sweden	marketed	Cancer vaccine / Autologous cell therapy
Autologous platelets rich plasma	Autologous platelets rich plasma	Mostafa Hassanein, Msc	marketed	Autologous cell therapy / Regenerative medicine product
Leukocyte rich platelet rich plasma	Leukocyte rich platelet rich plasma	University Hospitals Cleveland Medical Center	marketed	Autologous cell therapy / Regenerative medicine product
3ml-Rejuvinex	3ml-Rejuvinex	Seoul National University Bundang Hospital	marketed	Autologous cell therapy

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Autologous cell therapy class)

Tetec AG · 2 drugs in this class
GC Cell Corporation · 1 drug in this class
Seoul National University Bundang Hospital · 1 drug in this class
Sewon Cellontech Co., Ltd. · 1 drug in this class
StemCyte, Inc. · 1 drug in this class
TiGenix n.v. · 1 drug in this class
Cook MyoSite · 1 drug in this class
UnicoCell Biomed CO. LTD · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). NOVOCART® 3D plus — Competitive Intelligence Brief. https://druglandscape.com/ci/novocart-3d-plus. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing